RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerEarly phase 1

Registered title, quoted from ClinicalTrials.gov

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)First Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06937567, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Tumor tissue must be available either from prior tumor biopsy or by providing new tumor specimens.

    Inclusion criterion 4

  3. Non-hematological toxicity from prior treatment (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has not resolved to ≤ CTCAE grade 1 (except for hair loss and peripheral sensory neuropathy).

    Exclusion criterion 6

    Patients who have previously received CDH17 CAR-T therapy, except those who received CAR-T infusion within this study.

    Exclusion criterion 8

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    Inclusion criterion 6

  5. At least one measurable lesion as defined by RECIST v1.1 criteria.

    Inclusion criterion 3

  6. Positive hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) with peripheral HBV DNA levels above the lower limit of detection.

    Exclusion criterion 2

    Positive hepatitis C virus (HCV) antibody with peripheral HCV RNA levels above the lower limit of detection.

    Exclusion criterion 3

    Positive HIV antibody.

    Exclusion criterion 4

    History of another malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer or in situ cancers.

    Exclusion criterion 21

  7. Female participants of childbearing potential must have a negative pregnancy test.

    Inclusion criterion 9

    Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use effective contraception during the study and for 1 year after the final cell infusion.

    Inclusion criterion 10

    Women who are pregnant or breastfeeding.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06937567, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histopathologically confirmed malignant solid tumors, including but not limited to colorectal cancer, gastric cancer, pancreatic cancer, and biliary tract tumors.
  • Patients must have failed standard treatments, be intolerant to standard treatments, or lack effective treatment options.
  • At least one measurable lesion as defined by RECIST v1.1 criteria.
  • Tumor tissue must be available either from prior tumor biopsy or by providing new tumor specimens.
  • Tumor specimens must be confirmed as CDH17-positive by immunohistochemistry (IHC) or immunocytochemistry (ICC) staining.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Expected survival time ≥ 3 months.
  • Appropriate organ function: hematological: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹/L. Hemoglobin (HGB) ≥ 80 g/L; Platelet count (PLT) ≥ 75 × 10⁹/L. Liver Function: aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3.0 × ULN (≤ 5.0 × ULN for patients with primary liver tumors or liver metastases); total bilirubin ≤ 1.5 × ULN (≤ 3.0 × ULN for patients with primary liver tumors or liver metastases; ≤ 3 × ULN for Gilbert's syndrome with direct bilirubin ≤ 1.5 × ULN). Coagulation: international normalized ratio (INR) ≤ 1.5 × ULN (unless on therapeutic anticoagulants); activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (unless on therapeutic anticoagulants). Renal Function: serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL/min (based on Cockcroft-Gault formula). Cardiac Function: left ventricular ejection fraction (LVEF) ≥ 50% (confirmed by echocardiography). Pulmonary Function: resting oxygen saturation (SpO₂) > 92% without supplemental oxygen.
  • Female participants of childbearing potential must have a negative pregnancy test.
  • Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use effective contraception during the study and for 1 year after the final cell infusion.
  • Willingness to sign the informed consent form, demonstrating understanding of the study and agreement to comply with study procedures.

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Positive hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) with peripheral HBV DNA levels above the lower limit of detection.
  • Positive hepatitis C virus (HCV) antibody with peripheral HCV RNA levels above the lower limit of detection.
  • Positive HIV antibody.
  • Positive syphilis-specific and non-specific antibody tests.
  • Non-hematological toxicity from prior treatment (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has not resolved to ≤ CTCAE grade 1 (except for hair loss and peripheral sensory neuropathy).
  • Prior allogeneic tissue or organ transplant (including bone marrow, stem cell, liver, kidney, etc.), except for transplants not requiring immunosuppression (e.g., corneal or hair transplantation).
  • Patients who have previously received CDH17 CAR-T therapy, except those who received CAR-T infusion within this study.
  • Underwent major surgery within 4 weeks prior to signing informed consent and has not fully recovered, or has a history of serious unresolved trauma.
  • Known central nervous system (CNS) metastases (with exceptions for asymptomatic brain metastases or stable clinical symptoms).
  • Severe active infections or pulmonary diseases requiring systemic corticosteroid treatment within 6 months prior to signing informed consent.
  • Symptomatic congestive heart failure (NYHA class II-IV), severe aortic stenosis, or symptomatic mitral stenosis.
  • ECG showing QTc > 450 ms or QTc > 480 ms with bundle branch block.
  • Uncontrolled hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg).
  • Cerebrovascular accidents within 6 months prior to signing informed consent.
  • Active, chronic, or recurrent severe autoimmune diseases requiring immunosuppressive treatment (with exceptions).
  • Any form of primary or secondary immunodeficiency.
  • Risk of organ perforation or bleeding as judged by the investigator.
  • Severe systemic hypersensitivity reactions to study drugs/components. - Received live attenuated vaccines within 4 weeks prior to signing informed consent.
  • Participated in another clinical study within 4 weeks prior to signing informed consent.
  • History of another malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer or in situ cancers.
  • Diagnosed with neuropsychiatric disorders or any condition deemed by the investigator as unsuitable for participation.

Quoted from ClinicalTrials.gov, NCT06937567, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06937567, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06937567